Cost Effectiveness of Micronised Fenofibrate and Simvastatin in the Short Term Treatment of Type IIa and Type IIb Hyperlipidaemia

Kirchgässler, Klaus U.; Schiffner-Rohe, J.; Stahlheber, U.

doi:10.2165/00019053-199712020-00014

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, these studies were based on estimates of benefit from changes in lipid profiles and not data from mortality trials with fenofibrate, since the latter do not exist. Kirchgassler et al 160 used data from two randomized controlled trials 67,129 (Table 2) in retrospective fashion to compare the cost-effectiveness of simulated 12-week courses of micronized fenofibrate 200 mg/d (n = 88) and simvastatin 20 mg/d (n = 85) in the treatment of types IIa and IIb hyperlipidemia. Successful treatment was defined as a 15% decrease in LDL-C (type IIa) and a 15% decrease in LDL-C plus a 30% decrease in TG (type IIb).…”

Section: Micronized Fenofibratementioning

confidence: 99%

“…These results were confirmed by sensitivity analysis. 160 Perreault et al 161 conducted a study of the lifetime costeffectiveness of HMG-CoA reductase inhibitors and fibrates in hyperlipidemia management. Analyses were conducted using middle-aged men and women who had no history of CAD with either primary type IIa or IIb hyperlipidemia.…”

Section: Micronized Fenofibratementioning

confidence: 99%

See 1 more Smart Citation

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Guay

1999

Ann Pharmacother

View full text Add to dashboard Cite

Fenofibrate reduces serum TG, total cholesterol, and LDL-C, and raises HDL-C to clinically relevant degrees. Its spectrum of activity appears to exceed that recommended for types IV and V hyperlipidemia to encompass types IIa, IIb, and III hyperlipidemias as well. To this extent, it may be considered a broader-spectrum fibrate than is indicated by its FDA approval. Adverse effects of fenofibrate appear to be similar to those of other fibrates and require routine monitoring (clinical, liver function). Long-term safety data are readily available from drug registries in many countries where the product has been available for nearly two decades. Cost-effectiveness studies comparing fenofibrate with other hypolipidemics demonstrate benefits of fenofibrate over simvastatin in types IIa and IIb hyperlipidemia. The need for dosage titration of the micronized preparation from 67 mg/d upward to a final dose of 200 mg/d is also not supported by peer-reviewed literature (except in the case of renal impairment). Although preliminary data on plaque regression are encouraging, published clinical studies evaluating the impact of fenofibrate on cardiovascular morbidity and mortality are awaited. Micronized fenofibrate is worthy of formulary inclusion.

show abstract

Section: Micronized Fenofibratementioning

confidence: 99%

Section: Micronized Fenofibratementioning

confidence: 99%

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Guay

1999

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…24) Another study, in which fenoˆbrate (200 mg/day) and simvastatin (20 mg/day) were compared in type IIb hyperlipidemia treatment, fenoˆbrate was reported to be more cost eŠective. 25) When fenoˆbrate, bezabrate, gemˆbrozil, ‰uvastatin, lovastatin and simvastatin were compared in type IIa and type IIb hyperlipidemia patient groups, simvastatin was the most cost eŠective in the combined patient group (types IIa and IIb), but in the type IIb patient group, fenoˆbrate was more cost eŠective than simvastatin. 14) Our results are in agreement with the results of these studies and suggest that medical costs could be reduced by prescribing fenoˆbrate to patients with type IIb or type IV hyperlipidemia.…”

Section: Discussionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Anti-Hyperlipidemic Agent Fenofibrate

Hayakawa

Shimoyama²,

Sekiya³

et al. 2002

YAKUGAKU ZASSHI

View full text Add to dashboard Cite

We evaluated the economic e‹ciency as well as the clinical eŠectiveness on serum lipid levels of a change in drug therapy from bezaˆbrate or a 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor to fenoˆbrate. Subjects were 26 outpatients suŠering from type IIb or type IV hyperlipidemia who visited our hospital between October 2000 and January 2001. Medication doses, and serum lipid levels were recorded prior to the change to fenoˆbrate and at 6 months after the change. Medical costs were also calculated at the same time points. A signiˆcant reduction in medical costs of 14.9％ was observed following the change to fenoˆbrate. Serum lipid levels were not signiˆcantly diŠerent, although an increase in low density lipoprotein-cholesterol (LDL-cholesterol) was observed in patients changing from the HMG-CoA reductase inhibitor. The actual drug costs were reduced by 21.8％ in the bezaˆbrate to fenoˆbrate group and by 23.7％ in the HMG-CoA reductase inhibitor to fenoˆbrate group. Although the drug costs of changing to fenoˆbrate decreased signiˆcantly, other costs remained almost unchanged.

show abstract

Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation

Najib

2002

Clinical Therapeutics

View full text Add to dashboard Cite

Cost Effectiveness of Micronised Fenofibrate and Simvastatin in the Short Term Treatment of Type IIa and Type IIb Hyperlipidaemia

Cited by 8 publications

References 0 publications

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Pharmacoeconomic Evaluation of Anti-Hyperlipidemic Agent Fenofibrate

Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation

Contact Info

Product

Resources

About